Ad-hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1842 results
October 2022
-
Ad-hoc release
Novartis maintient sa dynamique de croissance et confirme les prévisions de l’exercice 2022 pour le Groupe
Annonce événementielle au sens de l’art. 53 RC Chiffre d’affaires du T3 en hausse de +4% tcc1 (-4% USD) Innovative Medicines (IM) : hausse du chiffre d’affaires de +4% tcc (-3% USD),… -
Ad-hoc release
Novartis investigational oral monotherapy iptacopan demonstrates clinically meaningful superiority over anti-C5 treatment in Phase III APPLY-PNH study
Ad hoc announcement pursuant to Art. 53 LRPhase III APPLY-PNH trial met its two primary endpoints for superiority versus anti-C5 treatment in adult paroxysmal nocturnal hemoglobinuria (PNH) patients… -
Press release
Novartis receives positive CHMP opinion for Pluvicto® for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer
Phase III VISION trial showed Pluvicto® plus best standard of care significantly improved survival for patients with pre-treated PSMA-positive mCRPC1 Approximately 473,000 prostate cancer cases and… -
Featured News
World Sight Day 2022: Raising awareness on the importance of eye health
Through the Avoidable Blindness Program, Novartis is working with partners to strengthen eye health in sub-Saharan Africa.
-
Story People and Culture
In neuroscience, “an inflection point in knowledge and technology”
-
Story Patient Perspectives
Let’s Talk About the C Word: Navigating a cancer diagnosis and the life beyond it with Leanne Pero
Leanne Pero discusses her experiences of life before, during and after breast cancer, and how it inspired her to advocate for herself and others like her.
September 2022
-
Press release
Novartis unveils new focused strategy, underpinned by eight potential multi-billion dollar peak sales brands & deep pipeline, at Meet the Management event
Transformation to pure-play Innovative Medicines company nears completion Focusing strategy on five core Therapeutic Areas, key technology platforms, and the US Advancing eight in-… -
Ad-hoc release
Novartis plans to petition the U.S. Supreme Court to uphold validity of the Gilenya® (fingolimod) dosing regimen patent
Ad hoc announcement pursuant to Art. 53 LR Basel, 21 September, 2022 — Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) has denied its… -
Press release
Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trial
ROSALIA study met primary endpoints, confirming proposed biosimilar denosumab matches reference product in terms of pharmacokinetics, pharmacodynamics, efficacy, safety and immunogenicity in… -
Press release
Novartis statement regarding competition authority investigation into assertion of a patent
Company confident to clarify legitimacy of its position and fully cooperating with authorities Basel, September 15, 2022 — Novartis today confirms that it has been contacted by the Swiss… -
Press release
Novartis invests in early technical development capabilities for next-generation biotherapeutics
Multi-year investment of USD 300m will create integrated scientific environment to deliver on increasing growth and diversity of biotherapeutics portfolio Enhanced capacity and processes… -
Featured News
Novartis Hematology: Working to help ensure patients are getting the access they need
Developing treatments for blood cancers and serious blood disorders is important, but it is only part of the equation. We also need to help ensure those who may need our therapies can get them.